



**Supplemental Figure S6** Gene editing results using the CRISPR/Cas9 system. (**A**, **B**, **C**) Gene editing efficiencies (produced indels) for the target genes *PLK1* (**A**), *KIF11* (**B**), and *INCENP* (**C**) produced with two different solid-phase (SP) transfections (either simultaneously co-transfected recombinant Cas9 endonuclease with gRNA or an all-in-one cDNA) on the two cell lines HeLa and HEK293T (lanes 2-5). The first lane shows the uncut PCR product (same product as in lane 2, without T7E1 endonuclease). The transfections were performed in 384-multiwell plates. Cells were lysed 48 hours post transfection, followed by PCR target amplification and genomic cleavage detection assay. (**D**) Gene editing efficiencies for the depicted target genes, produced in HeLa cells after lentiviral transduction of the CRISPR constructs (lanes 2,4 and 6). Lanes 1,3 and 5 show the respective uncut PCR products (without T7E1 endonuclease). The transductions were performed in 384-multiwell plates. Cells were lysed 48 hours post transduction, followed by PCR target amplification and genomic cleavage detection assay. (**E**) Gene editing efficiencies for the depicted target genes, produced in HeLa and HEK293T cells after liquid-phase (LP) transfection of simultaneously co-transfected recombinant Cas9 endonuclease with gRNA. The transfections were performed in 96-multiwell plates. Cells were lysed 48 hours post transfection, followed by PCR target amplification and genomic cleavage detection assay.